Arthneeti
CR

Corona Remedies Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Corona Remedies Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹2,143
Market cap₹12.8K Cr
P/E60.6
Updated23 Aug 2026
Read4 min read

The short version

CORONA Remedies targets a consistent revenue growth of around 15% annually, outpacing the Indian Pharmaceutical Market (IPM). CORONA Remedies targets consistent mid-teen revenue growth (~15%) and high-teen PAT growth (~20%) annually.

From Corona Remedies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • CORONA Remedies targets a consistent revenue growth of around 15% annually, outpacing the Indian Pharmaceutical Market (IPM).
  • PAT (Profit After Tax) growth expectation is high-teens to 20% annually.
  • Volume growth contributes approximately 5% to overall growth, supported by new product introductions.
  • The company plans to launch 8 to 10 new products yearly, primarily organically (95%), with a few acquisitions (5-7%).
  • Expansion includes entry into new therapies like infertility, rheumatology, and spine.
  • Growth is driven by chronic and semi-chronic segments, constituting around 70-72% of revenue.
  • Increasing market share through specialist and super-specialist prescribers is a key focus.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Corona Remedies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Recently capitalized a 600 kg manufacturing line, unlocking 40% capacity.
  • Planning to consider adding a new manufacturing block around FY'28-'29 to support future growth.
  • Currently, no immediate need to add new lines such as injectable or biosimilar lines; will evaluate at the appropriate time.
  • Maintain a balanced mix of 65% in-house manufacturing and 35% CDMO/CMO outsourcing.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Corona Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention details about the current or expected order book or pending orders for CORONA Remedies Limited. However, from the discussion, the following points related to order flow and growth can be inferred: - CORONA Remedies is focusing on organic growth with 15% revenue growth guidance. - The company has recently launched and is launching new products including those from the Bayer portfolio, biosimilars, and GLP-1 injectable by March 2026. - The company is expanding capacities, including unlocking 40% capacity by the 600 kg manufacturing line. - Plans for additional plant expansion are being considered for FY'28-FY'29 to support growth.

2 more points management made on order book & pipeline

Corona Remedies Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹353 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Corona Remedies's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences Ltd (Q3 FY26)

    180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals Ltd (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…

  • Morepen Laboratories Ltd (Q3 FY26)

    488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

  • Jubilant Pharmova Ltd (Q3 FY26)

    2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Corona Remedies Ltd Q3 FY26 results?

CORONA Remedies targets a consistent revenue growth of around 15% annually, outpacing the Indian Pharmaceutical Market (IPM). CORONA Remedies targets consistent mid-teen revenue growth (~15%) and high-teen PAT growth (~20%) annually.

What is Corona Remedies Ltd share price analysis?

Corona Remedies Ltd currently shows a neutral. The stock trades at a P/E of 60.6 with a market cap of ₹12,823 Cr. Investors should review the full earnings analysis for detailed insights.

Is Corona Remedies Ltd planning capital expenditure?

Recently capitalized a 600 kg manufacturing line, unlocking 40% capacity.

Keep Corona Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.